BACKGROUND: There is limited information about the safety of chronic nonsteroidal anti-inflammatory drugs (NSAIDs) in hypertensive patients with coronary artery disease. METHODS: This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease. At each visit, patients were asked by the local site investigator if they were currently taking NSAIDs. Patients who reported NSAID use at every visit were defined as chronic NSAID users, while all others (occasional or never users) were defined as nonchronic NSAID users. The primary composite outcome was all-cause death, nonfatal myocardial infarction, or nonfatal stroke. Cox regression was used to construct a multivariate analysis for the primary outcome. RESULTS: There were 882 chronic NSAID users and 21,694 nonchronic NSAID users (n = 14,408 for never users and n=7286 for intermittent users). At a mean follow-up of 2.7 years, the primary outcome occurred at a rate of 4.4 events per 100 patient-years in the chronic NSAID group, versus 3.7 events per 100 patient-years in the nonchronic NSAID group (adjusted hazard ratio [HR] 1.47; 95% confidence interval [CI], 1.19-1.82; P=.0003). This was due to an increase in cardiovascular mortality (adjusted HR 2.26; 95% CI, 1.70-3.01; P<.0001). CONCLUSION: Among hypertensive patients with coronary artery disease, chronic self-reported use of NSAIDs was associated with an increased risk of adverse events during long-term follow-up.
BACKGROUND: There is limited information about the safety of chronic nonsteroidal anti-inflammatory drugs (NSAIDs) in hypertensivepatients with coronary artery disease. METHODS: This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease. At each visit, patients were asked by the local site investigator if they were currently taking NSAIDs. Patients who reported NSAID use at every visit were defined as chronic NSAID users, while all others (occasional or never users) were defined as nonchronic NSAID users. The primary composite outcome was all-cause death, nonfatal myocardial infarction, or nonfatal stroke. Cox regression was used to construct a multivariate analysis for the primary outcome. RESULTS: There were 882 chronic NSAID users and 21,694 nonchronic NSAID users (n = 14,408 for never users and n=7286 for intermittent users). At a mean follow-up of 2.7 years, the primary outcome occurred at a rate of 4.4 events per 100 patient-years in the chronic NSAID group, versus 3.7 events per 100 patient-years in the nonchronic NSAID group (adjusted hazard ratio [HR] 1.47; 95% confidence interval [CI], 1.19-1.82; P=.0003). This was due to an increase in cardiovascular mortality (adjusted HR 2.26; 95% CI, 1.70-3.01; P<.0001). CONCLUSION: Among hypertensivepatients with coronary artery disease, chronic self-reported use of NSAIDs was associated with an increased risk of adverse events during long-term follow-up.
Authors: Emil Loldrup Fosbøl; Fredrik Folke; Søren Jacobsen; Jeppe N Rasmussen; Rikke Sørensen; Tina Ken Schramm; Søren S Andersen; Søren Rasmussen; Henrik Enghusen Poulsen; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason Journal: Circ Cardiovasc Qual Outcomes Date: 2010-06-08
Authors: Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245
Authors: Barbara K Martin; Christine Szekely; Jason Brandt; Steven Piantadosi; John C S Breitner; Suzanne Craft; Denis Evans; Robert Green; Michael Mullan Journal: Arch Neurol Date: 2008-05-12
Authors: Andrew T Chan; JoAnn E Manson; Christine M Albert; Claudia U Chae; Kathryn M Rexrode; Gary C Curhan; Eric B Rimm; Walter C Willett; Charles S Fuchs Journal: Circulation Date: 2006-03-13 Impact factor: 29.690
Authors: M-W Sohn; L M Manheim; R W Chang; P Greenland; M C Hochberg; M C Nevitt; P A Semanik; D D Dunlop Journal: Osteoarthritis Cartilage Date: 2014-07-18 Impact factor: 6.576
Authors: Christina M Vitto; Joseph D Lykins V; Hillary Wiles-Lafayette; Taruna K Aurora Journal: Curr Hypertens Rep Date: 2022-05-20 Impact factor: 4.592
Authors: José Pedro Henriques Patrício; Jorge Pinto Pereira Barbosa; Rui Miguel Monteiro Ramos; Nuno Filipe Pimenta Antunes; Pedro Carlos Santos de Melo Journal: Clin Drug Investig Date: 2013-03 Impact factor: 2.859
Authors: E D Foster; J E Cavanaugh; W G Haynes; M Yang; A K Gerke; F Tang; P M Polgreen Journal: Epidemiol Infect Date: 2013-01-03 Impact factor: 2.451
Authors: Anthony A Bavry; Fridtjof Thomas; Matthew Allison; Karen C Johnson; Barbara V Howard; Mark Hlatky; JoAnn E Manson; Marian C Limacher Journal: Circ Cardiovasc Qual Outcomes Date: 2014-07-08